Jagsonpal Pharmaceuticals Ltd Share Price

394.95
(3.19%)
Jul 26, 2024|03:32:17 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open400
  • Day's High409
  • 52 Wk High514.85
  • Prev. Close382.75
  • Day's Low388.95
  • 52 Wk Low273.6
  • Turnover (lac)1,224.48
  • P/E44.99
  • Face Value5
  • Book Value68.6
  • EPS8.49
  • Mkt. Cap (Cr.)1,044.92
  • Div. Yield1.31
No Records Found

Jagsonpal Pharmaceuticals Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

400

Prev. Close

382.75

Turnover(Lac.)

1,224.48

Day's High

409

Day's Low

388.95

52 Week's High

514.85

52 Week's Low

273.6

Book Value

68.6

Face Value

5

Mkt Cap (₹ Cr.)

1,044.92

P/E

44.99

EPS

8.49

Divi. Yield

1.31

Jagsonpal Pharmaceuticals Ltd Corporate Action

23 May 2023

12:00 AM

Dividend

Dividend Amount: 5

Record Date: 21 Aug, 2023

arrow

5 Aug 2023

12:00 AM

AGM

Announcement Date: 05 Aug, 2023

arrow

13 May 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

Jagsonpal Pharmaceuticals Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Jagsonpal Pharmaceuticals Ltd SHAREHOLDING SNAPSHOT

27 Jul, 2024|06:50 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 43.29%

Foreign: 43.29%

Indian: 24.74%

Non-Promoter- 1.95%

Institutions: 1.95%

Non-Institutions: 30.00%

Custodian: 0.00%

Share Price

Jagsonpal Pharmaceuticals Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

13.1

13.1

13.1

13.1

Preference Capital

0

0

0

0

Reserves

145.79

119.66

108.83

97.93

Net Worth

158.89

132.76

121.93

111.03

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

187.94

158.56

126.53

143.87

yoy growth (%)

18.52

25.31

-12.05

0.26

Raw materials

-80.77

-56.18

-61.11

-58.94

As % of sales

42.97

35.43

48.29

40.97

Employee costs

-53.98

-50.37

-41.87

-40.95

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Profit before tax

21.87

9.41

-11.62

1.59

Depreciation

-1.08

-1.12

-0.31

-1.99

Tax paid

-4.81

-1.54

0.07

-2.53

Working capital

16.88

-7.6

-14.27

6.47

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2021Mar-2020Mar-2018Mar-2017

Growth matrix (%)

Revenue growth

18.52

25.31

-12.05

0.26

Op profit growth

123.59

-176.82

-292.53

-51.15

EBIT growth

125.46

-190.51

-358.5

-54.72

Net profit growth

116.72

-168.14

-197.35

264.59

View Ratios

No Record found

Jagsonpal Pharmaceuticals Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,665.8

130.913,99,537.26867.60.815,536.9998.75

Zydus Lifesciences Ltd

ZYDUSLIFE

1,205.8

35.291,21,311.571,405.20.253,172.6156.19

Cipla Ltd

CIPLA

1,500.05

32.611,21,119.621,038.40.573,444.92346.41

Divis Laboratories Ltd

DIVISLAB

4,547

76.671,20,781.575310.662,259507.93

Dr Reddys Laboratories Ltd

DRREDDY

6,853.2

26.691,14,348.411,034.80.585,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Jagsonpal Pharmaceuticals Ltd

Management

Register Office

Registrar Office

Managing Director

Manish Gupta

Chairman & Non Executive Dir.

Harsha Raghavan

Independent Director

Debasis Bikash Nandy

Independent Director

Radhika Dudhat

Independent Director

Pallavi Dinodia

Non Executive Director

Prithipal Singh Kochhar

Company Sec. & Compli. Officer

Abhishek Joshi

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Promoted by J S Kochhar in 1978, Jagsonpal Pharmaceuticals is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs. Simultaneously it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd.The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India. It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product. In 1994, the company has also promoted Aresco Financial Services, a new financial company.The Companys R&D activities have resulted in manufacturing process upgradation, improving packaging, and cost containment. Its R&D activities are geared towards development of new product technologies which can be commercialised in future.It has tied up with Lycored Natural Products Industries (LNP) of Israel, to launch a completely natural Lycopene bioactive product, Lycored, in India and SouthEast Asia.In the fiscal 2001, the companys sales grew by 15% to Rs 136.52 crore and the profit at the net level was up 8% to Rs 10.15 crore. This was achieved against heavy odds, such as, sluggish market trends, lower growth rate of the industry and severe competition from dr
Read More

Company FAQs

What is the Jagsonpal Pharmaceuticals Ltd share price today?

Down Arrow

The Jagsonpal Pharmaceuticals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹394.95 today.

What is the Market Cap of Jagsonpal Pharmaceuticals Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Jagsonpal Pharmaceuticals Ltd is ₹1044.92 Cr. as of 26 Jul ‘24

What is the PE and PB ratio of Jagsonpal Pharmaceuticals Ltd?

Down Arrow

The PE and PB ratios of Jagsonpal Pharmaceuticals Ltd is 44.99 and 5.39 as of 26 Jul ‘24

What is the 52 Week High and Low of Jagsonpal Pharmaceuticals Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Jagsonpal Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Jagsonpal Pharmaceuticals Ltd is ₹273.6 and ₹514.85 as of 26 Jul ‘24

What is the CAGR of Jagsonpal Pharmaceuticals Ltd?

Down Arrow

Jagsonpal Pharmaceuticals Ltd's CAGR for 5 Years at 76.26%, 3 Years at 30.67%, 1 Year at 1.88%, 6 Month at -0.69%, 3 Month at 14.82% and 1 Month at 12.54%.

What is the shareholding pattern of Jagsonpal Pharmaceuticals Ltd?

Down Arrow

The shareholding pattern of Jagsonpal Pharmaceuticals Ltd is as follows:
Promoters - 68.04 %
Institutions - 1.95 %
Public - 30.01 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.